Search clinical trials for: Tiotropium (SpirivaTM)

Total 414 results

Boehringer Ingelheim
Pfizer

Completed

A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma

Asthma

Germany, Hungary, Latvia, Lithuania, Russian Federation, Ukraine
Boehringer Ingelheim

Completed

Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Tiotropium / Respimat One-Year Study

Pulmonary Disease, Chronic Obstructive

Austria, Canada, Spain, United States, Finland, Italy, Russian Federation, United Kingdom, New Zealand, Australia, France, Greece, Ireland, Netherlands, South Africa
Boehringer Ingelheim

Completed

Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

United States
Novartis

Completed

Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Germany
University of Dundee
Almirall Limited

Completed

Evaluation of Long-Acting Muscarinic Antagonists in COPD (MAN04)

Pulmonary Disease, Chronic Obstructive

United Kingdom
Boehringer Ingelheim
Pfizer

Completed

Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Canada
Boehringer Ingelheim

Completed

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

Pulmonary Disease, Chronic Obstructive

Canada, United States
Boehringer Ingelheim

Completed

A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale

Pulmonary Disease, Chronic Obstructive

United States, Germany
Boehringer Ingelheim

Completed

Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma

Pulmonary Disease, Chronic Obstructive | Asthma

Netherlands, Germany, Belgium, France, Canada, Italy, South Africa, Denmark
GlaxoSmithKline

Completed

Effect of GSK1160724 In Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Czech Republic, Denmark, Finland, Germany, South Africa, Spain, United Kingdom
Boehringer Ingelheim

Completed

Japan Long-term Safety for Tiotropium Plus Olodaterol

Pulmonary Disease, Chronic Obstructive

Japan
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)

Asthma

United States, Australia, Canada, Denmark, Germany, Italy, Japan, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Turkey, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Terminated

Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)

Pulmonary Disease, Chronic Obstructive
Novartis

Completed

Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.

COPD

Denmark
Novo Nordisk A/S

Completed

Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Sweden, Denmark
Steno Diabetes Center Copenhagen
Juvenile Diabetes Research Foundation; Oeresund Diabetes Academy

Completed

Anti-Interleukin-1 in Diabetes Action (AIDA)

Type 1 Diabetes

Spain, Denmark, Netherlands, Germany, Italy, Poland, Switzerland
Tanta University

Completed

Three Treatment of Chronic Obstructive Pulmonary Disease Patients

COPD
AstraZeneca

Completed

Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Boehringer Ingelheim

Completed

A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment

Pulmonary Disease, Chronic Obstructive

Taiwan
Boehringer Ingelheim

Completed

Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

United States, Germany, Romania, Russian Federation, Spain, Bulgaria, Canada, Hungary, Argentina
Novartis Pharmaceuticals

Completed

Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients (FAVOR)

Chronic Obstructive Pulmonary Disease | COPD

Germany
Pearl Therapeutics, Inc.

Completed

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Boehringer Ingelheim

Completed

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Tiotropium Bromide in Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Ireland, Israel, Italy, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, Switzerland, United Kingdom
Boehringer Ingelheim

Completed

Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).

Pulmonary Disease, Chronic Obstructive

Portugal
Boehringer Ingelheim

Completed

Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients

Pulmonary Disease, Chronic Obstructive

Canada, Germany, United States, Australia
National University of Malaysia

Completed

Tiotropium Respimat Administration With and Without Aerochamber Disease (COPD)

Chronic Obstructive Pulmonary Disease

Malaysia
Boehringer Ingelheim

Completed

Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients

Pulmonary Disease, Chronic Obstructive

Belgium, Canada, Netherlands, Germany
Boehringer Ingelheim

Completed

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Dose Finding Study in COPD

Pulmonary Disease, Chronic Obstructive

Netherlands, Belgium, United States
Novartis Pharmaceuticals

Completed

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

Colombia, India, Korea, Republic of, Poland, Croatia, Estonia, Hungary, United Kingdom, Israel, Latvia, Turkey, Argentina, Panama, Mexico, Russian Federation, Serbia, Slovenia
Boehringer Ingelheim

Completed

Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Mechanisms of Dyspnea Relief During Exercise in COPD Patients Following Treatment With Tiotropium (Spiriva)

Pulmonary Disease, Chronic Obstructive

Canada
Boehringer Ingelheim

Completed

High Dose Trial in COPD

Pulmonary Disease, Chronic Obstructive

United States
Novartis Pharmaceuticals

Completed

Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Australia, New Zealand
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

Asthma

United States, Brazil, China, Colombia, Germany, India, Japan, Mexico, Peru, Poland, Romania
Boehringer Ingelheim

Completed

A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Nephron Pharmaceuticals Corporation
Rho, Inc.

Completed

Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States
Chinese University of Hong Kong
Hoffmann-La Roche

Completed

A Study on Higher-dose Oseltamivir Treatment's Impact on Viral Clearance and Clinical Recovery in Adults Hospitalized With Influenza

Respiratory Tract Infections | Influenza

Hong Kong
University of Colorado, Denver
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Withdrawn

Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes

Type I Diabetes

United States
Verona Pharma plc

Completed

Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

COPD

United States, United Kingdom

3

Subscribe